Pancreatic Neuroendocine Neoplasms (pNETs)NCT07136701
Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics of EO- vs LO-PanNETs
An observational study of Pancreatic Neuroendocine Neoplasms (pNETs), run by Qilu Hospital of Shandong University at 2 sites in China.
Trial summary
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs). Read more about this study
- Who is it for?
- Ages 18 to 85 years
- Conditions the study is for
- Pancreatic Neuroendocine Neoplasms (pNETs)
- How many people
- 600 participants
- Where
- 2 sitesChina
- Study dates
- 31 Aug 2025to 31 Jul 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population comprised adult patients (≥18 years) diagnosed with pancreatic neuroendocrine tumors (PanNETs) between 2013 and 2024. All cases had a histopathologically confirmed diagnosis and received treatment at one of the participating centers. Patients were excluded if they had poorly differentiated neuroendocrine carcinoma, mixed neuroendocrine-non-neuroendocrine neoplasm, undefined tumor differentiation, recurrent disease, non-initial treatment, or a history of other malignancies.
Who may be able to join
- 18 years or older; histopathologically confirmed pancreatic neuroendocrine tumor by surgical resection or biopsy.
Who cannot join
- Pancreatic neuroendocrine carcinoma; incomplete pathological data; received antitumor treatment prior to presentation; with other malignanies or malignant history.
Trial locations and contacts
2 sites in 1 country. Contact the study team or a site near you to ask about taking part.
Changhao Gao, MMed contact
China2 sites, 2 recruiting
- Not yet recruiting
Qilu Hospital of Shandong University
Jinan, Shandong
Xiaoyang Chen, PhD, +86 185 6008 6888, qlyykyll@163.com
- Recruiting
Qilu Hospital of Shandong University
Jinan
Changhao Gao, MD, +86-17860624903, gaochanghao44@gmail.com
About this study
Official title: Study in Risk Factors, Prognosis, Clinicopathological and Metabolic Characteristics Between Early- and Late-Onset Pancreatic Neuroendocrine Tumors: A Multicenter Retrospective Study
The aim of this observational multicenter retrospective cohort study is to evaluate the differences in risk factors, prognosis, clinicopathological and metabolic characteristics between early-onset pancreatic neuroendocrine tumors (EO-PanNETs) and late-onset pancreatic neuroendocrine tumors (LO-PanNETs).
The main questions it aims to answer are:
Read more
Are there distinct clinical, pathological, and metabolic profiles in EO-PanNETs compared with LO-PanNETs? Do EO-PanNETs have different prognostic outcomes compared with LO-PanNETs? Researchers will compare EO-PanNET patients with LO-PanNET patients and with matched nonmalignant controls to assess differences in tumor characteristics and associated metabolic conditions.
Participants will:
Provide retrospective clinical, pathological, and metabolic data from hospital records.
Have survival and recurrence outcomes assessed through follow-up data review.
- Keywords
- EO-PanNET
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Early-onset pancreatic neuroendocrine tumors group | This group comprises patients diagnosed with pancreatic neuroendocrine tumors before the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers. | |
| Late-onset pancreatic neuroendocrine tumors group | This group comprises patients diagnosed with pancreatic neuroendocrine tumors at or after the age of 50 years. All cases were histopathologically confirmed and treated at one of the participating centers. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival
Measured: From date of randomization until the date of death from any cause or the date of the last follow-up, whichever came first, assessed up to 12 years
Secondary outcomes (3)
Disease-specific survival
Measured: From date of diagnosis until death due to PanNETs, up to 12 years
Progression-free survival
Measured: From date of diagnosis until the date of disease recurrence or death from any cause, whichever came first, assessed up to 12 years.
Disease-free survival
Measured: From date of surgery until first documented recurrence, metastasis, or death from any cause, assessed up to 12 years.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Aug 2025
- Study start31 Aug 2025
- Primary completion30 Jun 2026
- Study completion31 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic Neuroendocine Neoplasms (pNETs)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Qilu Hospital of Shandong University
- Sponsor type
- University, hospital or other
- Collaborators
- China-Japan Friendship Hospital, The Affiliated Hospital of Qingdao University, Qianfoshan Hospital
- Responsible party
- Principal investigator, Hanxiang Zhan, Qilu Hospital of Shandong University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07136701
- Sponsor's protocol ID
- KYLL-2025-07-004
- Status last verified
- Aug 2026
- First submitted
- 14 Aug 2025
- Last updated
- 13 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- Individual data sharing
- Yes